Comparison of Follitropin Delta and Follitropin Alfa in Combination With Menotropin (BONANZA)

March 4, 2026 updated by: Clinique Ovo

Comparison of Follitropin Delta and Follitropin Alfa in Combination With Menotropin (the BONANZA Study)

The goal of this retrospective study is to compare the effectiveness and cost-effectiveness of two mixed ovarian stimulation protocols in women undergoing in vitro fertilization (IVF).

The main questions it aims to answer are:

  • Does the combination of follitropin delta + HP-hMG result in a higher number of utilizable blastocysts per treatment cycle compared to follitropin alfa + HP-hMG?
  • Does the follitropin delta based mixed protocol reduce total gonadotropin dose and cost per usable blastocyst while maintaining or improving pregnancy outcomes?

Researchers will compare follitropin alfa (Gonal-F®) + HP-hMG (Menopur®) with follitropin delta (Rekovelle®) + HP-hMG (Menopur®) to determine which protocol improves ovarian response, embryology outcomes, pregnancy rates, and overall treatment cost-efficiency.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

846

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Quebec
      • Montreal, Quebec, Canada, H4P 2S4
        • Clinique ovo

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Women who underwent their first IVF cycle between 2018 and 2024 at the ovo clinic

Description

Inclusion Criteria:

  • Women between 18-45 years included
  • First ovarian stimulation cycle only
  • Patients who used mixed protocols combining menotropin and follitropin alfa or delta
  • Patients whose Rekovelle doses were prescribed using the algorithm based on AMH and weight.

Exclusion Criteria:

  • Patients who did not follow the algorithm to determine follitropin delta dosing and who required dose adjustments during the stimulation
  • Patients who took concomitant treatment, such as corticosteroids, low molecular weight heparin, nonsteroidal anti-inflammatory drugs, recombinant LH or intra-vaginal vasodilators
  • Oocytes donation or fertility preservation cycles

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Follitropin alfa (Gonal-F®) + HP-hMG (Menopur®)
Follitropin delta (Rekovelle®) + HP-hMG (Menopur®)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of utilizable blastocysts per treatment cycle
Time Frame: For IVF performed from January 2018 to December 2024
For IVF performed from January 2018 to December 2024

Secondary Outcome Measures

Outcome Measure
Time Frame
Number of stimulation days
Time Frame: For IVF performed from January 2018 to December 2024
For IVF performed from January 2018 to December 2024
Totals doses of rFSH, HP-hMG, and FSH
Time Frame: For IVF performed from January 2018 to December 2024
For IVF performed from January 2018 to December 2024
Costs of rFSH, HP-hMG, and FSH
Time Frame: For IVF performed from January 2018 to December 2024
For IVF performed from January 2018 to December 2024
Number of retrieved oocytes
Time Frame: For IVF performed from January 2018 to December 2024
For IVF performed from January 2018 to December 2024
Number of mature oocytes (MII)
Time Frame: For IVF performed from January 2018 to December 2024
For IVF performed from January 2018 to December 2024
Number of fertilized oocytes (2PN)
Time Frame: For IVF performed from January 2018 to December 2024
For IVF performed from January 2018 to December 2024
Total FSH/ usable blastocysts ratio
Time Frame: For IVF performed from January 2018 to December 2024
For IVF performed from January 2018 to December 2024
Pregnancy rates
Time Frame: For IVF performed from January 2018 to December 2024
For IVF performed from January 2018 to December 2024
Cost per blastocyst
Time Frame: For IVF performed from January 2018 to December 2024
For IVF performed from January 2018 to December 2024

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Clinique Ovo

Investigators

  • Principal Investigator: Isaac-Jacques Kadoch, MD, Clinique ovo

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 5, 2025

Primary Completion (Actual)

December 15, 2025

Study Completion (Actual)

December 15, 2025

Study Registration Dates

First Submitted

February 24, 2026

First Submitted That Met QC Criteria

March 4, 2026

First Posted (Actual)

March 9, 2026

Study Record Updates

Last Update Posted (Actual)

March 9, 2026

Last Update Submitted That Met QC Criteria

March 4, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • BONANZA

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on IVF Outcomes

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe